Tom 7, Nr 5 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-11-25
Wyświetlenia strony
2900
Wyświetlenia/pobrania artykułu
154
Radiochemioterapia niedrobnokomórkowego raka płuca w skojarzeniu z immunoterapią
Onkol Prakt Klin Edu 2021;7(5):288-290.
Streszczenie
W pracy przedstawiono aktualne zalecenia leczenia niedrobnokomórkowego raka płuca w stadium zaawansowania miejscowego z zastosowaniem radiochemioterapii i immunoterapii.
Słowa kluczowe: niedrobnokomórkowy rak płucachemioradioterapiaimmunoterapia
Referencje
- Butts C, Socinski MA, Mitchell PL, et al. START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15(1): 59–68.
- Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13): 2181–2190.
- Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103(19): 1452–1460.
- Bayman N, Blackhall F, McCloskey P, et al. How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer? Lung Cancer. 2014; 83(2): 117–125.
- Tsujino K, Kurata T, Yamamoto S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol. 2013; 8(9): 1181–1189.
- Schumacher A, Riesenbeck D, Braunheim M, et al. German Lung Cancer Cooperative Group. Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life. Lung Cancer. 2004; 44(1): 89–97.
- Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26(15): 2450–2456.
- Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015; 16(2): 187–199.
- Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015; 51(16): 2321–2329.
- Socinski MA, Özgüroğlu M, Villegas A, et al. PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20): 1919–1929.
- Gray JE, Villegas A, Daniel D, et al. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379(24): 2342–2350.
- Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC Trial. J Thorac Oncol. 2021; 16(5): 715–718.
- Hosoya K, Fujimoto D, Kawachi H, et al. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2019; 84(2): 275–280.
